Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. Cronos Group Inc.
  6. Summary
    CRON   CA22717L1013

CRONOS GROUP INC.

(CRON)
  Report
Delayed Quote. Delayed Toronto Stock Exchange - 09/28 05:00:00 pm
7.16 CAD   -3.76%
05:20pINSIDER SELL : Cannabis Sativa
MT
05:05pCANADA STOCKS - TSX falls 1.41% to 20,174.14
RE
04:32pMERIDA MERGER I : Leafly Names New CFO
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Toronto Stock Exchange
09/22/2021 09/23/2021 09/24/2021 09/27/2021 09/28/2021 Date
7.51(c) 7.6(c) 7.21(c) 7.44(c) 7.16 Last
304 360 214 801 291 514 334 966 282 724 Volume
+3.44% +1.20% -5.13% +3.19% -3.76% Change
More quotes
Estimated financial data (e)
Sales 2021 87,2 M 68,7 M 68,7 M
Net income 2021 -221 M -174 M -174 M
Net cash position 2021 1 215 M 957 M 957 M
P/E ratio 2021 -12,0x
Yield 2021 -
Sales 2022 152 M 119 M 119 M
Net income 2022 -159 M -125 M -125 M
Net cash position 2022 1 115 M 878 M 878 M
P/E ratio 2022 -17,8x
Yield 2022 -
Capitalization 2 777 M 2 189 M 2 188 M
EV / Sales 2021 17,9x
EV / Sales 2022 11,0x
Nbr of Employees 631
Free-Float 52,1%
More Financials
Company
Cronos Group Inc is a cannabinoid company. The Company is focused on cannabis research, technology and product development. The Company’s portfolio includes PEACE NATURALS, COVE, Spinach, Lord Jones and PEACE+. PEACE NATURALS a global wellness platform. The COVE and Spinach are adult-use brands. The Lord Jones and PEACE+ are hemp-derived cannabidiol (CBD) brands. The Company’s segments include United States and... 
Sector
Pharmaceuticals
Calendar
11/05 | 01:30pmPresentation
More about the company
Ratings of Cronos Group Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about CRONOS GROUP INC.
05:20pINSIDER SELL : Cannabis Sativa
MT
05:05pCANADA STOCKS - TSX falls 1.41% to 20,174.14
RE
04:32pMERIDA MERGER I : Leafly Names New CFO
MT
02:30pAURORA CANNABIS : targets more cost cuts on path to profitability
RE
10:01aAURORA CANNABIS BRIEF : MKM Partners Upgraded It to Neutral from Sell, Lifted PT to C$7 Fr..
MT
09:03aAURORA CANNABIS : Piper Sandler Trims Aurora Cannabis Sales Estimates After Fiscal Q4 Reve..
MT
07:34aVILLAGE FARMS INTERNATIONAL : Gets Option to Buy 80% of Leli Holland as Dutch Government T..
MT
07:10aAMP ALTERNATIVE MEDICAL PRODUCTS : Strikes Deal with Tilray to Market Aphria-Branded Medic..
MT
07:02aVILLAGE FARMS BRIEF : Enters Option Agreement to Buy 80% of Leli Holland, One of Ten Appli..
MT
06:12aAURORA CANNABIS : Guides to Fiscal 2022 First Half Operating Earnings as Cost Savings to M..
MT
03:01aPRESS RELEASE : Cannovum AG expands cannabis wholesale license and enters the active ingre..
DJ
09/27Cannabis producer Tilray wins dismissal of shareholder lawsuit in New York
RE
09/27AURORA CANNABIS : revenue falls short of expectations on lower pot demand
RE
09/27AURORA CANNABIS BRIEF : BNN TV Notes Adult Use Sales Down 45% To $19.5 Million From Year E..
MT
09/27AURORA CANNABIS : Down In US After Hours As Reports Q4 Revs Down Vs Year Ago; Cites "Clear..
MT
More news
News in other languages on CRONOS GROUP INC.
05:20pVENTE D'INITIÉS : Cannabis Sativa
02:30pAurora Cannabis vise de nouvelles réductions de coûts sur la voie de la rentabilité
10:18aPTA-NEWS : Rapid Dose Therapeutics Corp.: Rapid Dose Therapeutics begrüßte Premierminister..
10:17aLA VALEUR DU JOUR À WALL STREET AURO : les nuages se dissipent
09:03aPiper Sandler revoit à la baisse les estimations de ventes d'Aurora Cannabis après la d..
More news
Analyst Recommendations on CRONOS GROUP INC.
More recommendations
Chart CRONOS GROUP INC.
Duration : Period :
Cronos Group Inc. Technical Analysis Chart | CRON | CA22717L1013 | MarketScreener
Technical analysis trends CRONOS GROUP INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 13
Last Close Price 7,16 CAD
Average target price 8,40 CAD
Spread / Average Target 17,3%
EPS Revisions
Managers and Directors
Kurt T. Schmidt President & Chief Executive Officer
Robert L. Madore Chief Financial Officer
Michael Ryan Gorenstein Executive Chairman
Jason Marc Adler Independent Director
James D. Rudyk Lead Independent Director
Sector and Competitors